ÂÜŔňÂŇÂ×

His very accomplished 25-year career encompasses leadership and advisory positions in both scientific and commercial operations in startup biotech and medium-sized pharma companies.

Philip began his career as a Senior Staff Scientist in Molecular Oncology, before holding several Director of Oncology positions, (Pharmacology), at Ipsen where he was also the research representative on the Governance Board for the Ipsen Life Sciences Program at the Salk Institute.

Due to his distinguished scientific career in oncology, Philip’s advisory positions include a role as Scientific Advisor, Sales and Marketing Assistance at OncoVet Clinical Research, (OCR) in Lille, France, where he advised on the technical and scientific accuracy of published documents, as well as assisted in the design of animal studies. His expertise was also sought by the Montréal based Oncodesign, where he managed Business Development and Pharmacology Operations for North America, and for the US-based Fenney Law Group, where Philip served as advisor for scientific patents, relative to biology and oncology. His commercial experience also includes partner and asset evaluation, alliance management, in-licensing and out-licensing, and therapeutic area company direction.

Inspired by collaboration, Philip has been consistently recognized by leadership for promoting cross-functional partnership, a hallmark of the Double Rainbow culture. He enjoys working with enthusiastic teams and spearheading effective collaborations to accelerate the drug development process.

Philip received his B.S. from Utica College of Syracuse University, and his Ph.D. from the Pennsylvania State University, followed by postdoctoral fellowships at the National Institutes of Health (NIH), first in the National Heart, Lung and Blood Institute, (NHLBI Branch) and then at the National Cancer Institute, (NCI).